Clinical Trial News and Research

RSS

Synpromics, Cell Therapy Catapult to create stable producer cell lines for large-scale manufacture of viral vectors

Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing.

12 Jan 2016

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centres across the country -- with the hope that it could become one of a number of effective treatments available to treat Parkinson's.

12 Jan 2016

Researchers use quick screening method to identify, test promising anti-Ebola drugs

A quick screening method has been used for the first time in a standard open laboratory to identify and test promising anti-Ebola drugs. This approach increases the possibility of finding new therapies faster.

12 Jan 2016

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.

11 Jan 2016

Research could lead to new treatment for Rett Syndrome, other forms of autism

Penn State scientists have discovered a novel drug target and have rescued functional deficits in human nerve cells derived from patients with Rett Syndrome, a severe form of autism-spectrum disorder.

11 Jan 2016

New strategy may reduce growth of pancreatic cancers in patients with KRAS gene mutation

University of North Carolina Lineberger Comprehensive Cancer Center researchers have found a promising strategy that may limit the growth of pancreatic cancers in patients with a mutation in a gene called KRAS.

11 Jan 2016

Intake of Bimuno in early life benefits brain development

Clasado Biosciences Limited, the producers and suppliers of Bimuno® (B-GOS), a unique patented trans-galactooligosaccharide complex, and the Department of Psychiatry, University of Oxford, today announce the results of their latest pre-clinical study, demonstrating for the first time a major role of B-GOS in modulating brain development at the molecular level in early life stages.

11 Jan 2016

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine.

11 Jan 2016

NUS-led study discovers potential therapeutic approach against colorectal cancer

A study led by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum) and is the most common cancer in Singapore.

11 Jan 2016

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.

8 Jan 2016

Pancreatic cancer to surpass breast cancer to become third leading cause of deaths in U.S.

Pancreatic cancer is expected to surpass breast cancer to become the third leading cause of cancer-related deaths in the United States, according to the latest Cancer Statistics 2016 report, published today by the American Cancer Society in CA: A Cancer Journal for Clinicians.

8 Jan 2016

ImpediMed introduces L-Dex system for clinical assessment of lymphedema in U.S.

ImpediMed Limited, a global provider of medical technology to measure, monitor and manage fluid status in patients, has announced the U.S. commercial launch of its L-Dex system to aid in the clinical assessment of lymphedema.

7 Jan 2016

Integra Omnigraft Dermal Regeneration Matrix approved to treat certain diabetic foot ulcers

The U.S. Food and Drug Administration today approved a new indication for the Integra Omnigraft Dermal Regeneration Matrix (Omnigraft) to treat certain diabetic foot ulcers. The matrix device, which is made of silicone, cow collagen, and shark cartilage, is placed over the ulcer and provides an environment for new skin and tissue to regenerate and heal the wound.

7 Jan 2016

Elsevier's new open access journal features novel method to make cancer clinical trials more effective

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials.

7 Jan 2016

NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

A newly NIH funded clinical trial (NCT02528942) by University of Colorado Cancer Center investigators and collaborators at Beaumont Health in Michigan and the University of Texas Medical Branch is evaluating a new method for pinpointing and sparing healthy lung tissue during lung cancer radiotherapy.

7 Jan 2016

Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma.

7 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

Vtesse receives FDA's Breakthrough Therapy designation for VTS-270

Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.

6 Jan 2016

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

The Sohn Conference Foundation today announced a $50,000 grant to support funding of a Phase 2 cutting-edge pediatric clinical trial from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) now extending to New York City.

6 Jan 2016

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.

6 Jan 2016

Clinical Trial News and Research

Synpromics, Cell Therapy Catapult to create stable producer cell lines for large-scale manufacture of viral vectors

Cholesterol-lowering drug simvastatin could become effective treatment for Parkinson's

Researchers use quick screening method to identify, test promising anti-Ebola drugs

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Research could lead to new treatment for Rett Syndrome, other forms of autism

New strategy may reduce growth of pancreatic cancers in patients with KRAS gene mutation

Intake of Bimuno in early life benefits brain development

CTCA at Western announces launch of Phase II NivoPlus clinical trial

NUS-led study discovers potential therapeutic approach against colorectal cancer

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

Pancreatic cancer to surpass breast cancer to become third leading cause of deaths in U.S.

ImpediMed introduces L-Dex system for clinical assessment of lymphedema in U.S.

Integra Omnigraft Dermal Regeneration Matrix approved to treat certain diabetic foot ulcers

Elsevier's new open access journal features novel method to make cancer clinical trials more effective

NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

Pediatric oncologists devise new treatments for neuroblastoma

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

Vtesse receives FDA's Breakthrough Therapy designation for VTS-270

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer